Momcozy Stands Up for European Mums with its "Remove Breastfeeding Barriers, Give Mums Real Support" Campaign
LONDON, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Momcozy, companion to over 3 million mothers globally, is expanding its maternity services to Europe. Building on North American success, the brand's European campaign "Remove Breastfeeding Barriers, Give Mums Real Support" signals support for new and expectant mothers.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
A Momcozy survey reveals low awareness of wearable breast pumps in areas like Germany and France. Of the 80% using breast pumps, under 20% expressed familiarity with wearable options—the implication being that many mothers feel confined by traditional breastfeeding methods, losing significant personal time and freedom.
Informed by these findings, Momcozy’s campaign aims to be a support beacon for European mums, dismantling barriers through innovative products and supportive actions, and empowering mothers to reclaim autonomy during their breastfeeding journey.
Among its products, Momcozy brings its award-winning wearable breast pumps to Europe, offering a variety of options for the diverse needs of modern mums.
Momcozy’s flagship M5 epitomizes versatility, discretion, and portability, catering to modern mothers' dynamic needs. Weighing just 230g (8.1 oz.), this compact unit simplifies pumping, enabling mothers to pump effortlessly anywhere, anytime. Its ergonomic design and quiet motor (under 50 dB), ensure a discreet, confident pumping experience.
Besides products, Momcozy is amplifying its campaign with tangible community support. In November, it will host "Stand Up for Mums," a comedy event to vocalize the daily challenges faced by breastfeeding mothers.
Beyond this, Momcozy is committed to ongoing community support through future collaborations and initiatives, with details forthcoming.
“No matter where in the world, most new and expectant mothers face an uphill battle fulfilling their breastfeeding goals,” stated a Momcozy representative. "With our wearable breast pumps and community initiatives, we want European moms to know their voices are heard, and they have our unwavering support." She added, "We're excited for what comes next!"
About Momcozy
Since 2018, Momcozy has been bringing the best in comfort to mothers with wearable breast pumps, nursing bras and other mom caring products.
Endorsed by 3 million mothers in over 40 countries, Momcozy is a companion to women from pregnancy to early motherhood.
With continuous innovation and a commitment to creating cozy designs born from love, Momcozy is growing in reach and impact to make moms’lives easier around the world.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3f16d8c1-b926-4795-bb58-9c1e8c824f48
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Karolinska Development's portfolio company OssDsign expects fourth-quarter revenues to exceed market estimates6.12.2023 12:38:48 CET | Press release
STOCKHOLM, SWEDEN, December 6, 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that the portfolio company OssDsign expects revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary total revenues for the period October - November amount to SEK 25.2 million, mainly attributable to a continued strong market performance of the company's orthobiologic franchise and some extraordinary orders from a large hospital system. According to preliminary and unaudited data, sales of OssDsign Catalyst amounted to SEK 18.8 million during the period of October – November 2023, whereas OssDsign Cranial recorded sales of SEK 6.4 million. A complete financial statement for the fourth quarter will be presented in OssDsign’s year-end report for 2023, to be published on February 6, 2024. "OssDsign continues its strong growth journey, and we are confident that the company's new strategic direction to fully focus the business on its high-margin orthobiologic franchis
Karolinska Developments portföljbolag OssDsign bedömer att intäkterna för fjärde kvartalet kommer att överträffa marknadens förväntningar6.12.2023 12:38:48 CET | Pressemelding
STOCKHOLM, SVERIGE 6 december 2023. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att portföljbolaget OssDsign bedömer att intäkterna för det fjärde kvartalet 2023 kommer överträffa marknadens förväntningar. De preliminära totala intäkterna för perioden oktober – november uppgår till 25,2 MSEK, främst till följd av en fortsatt stark marknadsutveckling för bolagets ortobiologiprodukter och ett antal större ordrar från ett stort sjukhusnätverk. Enligt preliminära och oreviderade försäljningsdata för perioden oktober – november 2023 uppnåddes intäkter om 18,8 miljoner kronor för OssDsign Catalyst, medan intäkterna för OssDsign Cranial uppgick till 6,4 miljoner kronor. En fullständig finansiell rapport för det fjärde kvartalet kommer att presenteras i OssDsigns bokslutskommuniké för 2023, som publiceras den 6 februari 2024. ”OssDsign fortsätter sin starka tillväxtresa och vi är övertygade om att bolagets nya strategiska inriktning för att fullt fokusera verksamheten på sina o
XPENG G9 Achieves a Five-Star 2023 Safety Rating from Euro NCAP6.12.2023 11:00:00 CET | Press release
The new XPENG G9, now on sale in Europe, received a five-star 2023 safety rating from Euro NCAPThis is XPENG's second five-star safety rating for an international model following the new P7 in October; and its first SUV obtained both Euro NCAP and C-NCAP five-star ratings AMSTERDAM, Dec. 06, 2023 (GLOBE NEWSWIRE) -- XPENG Motors (“XPENG” or the “Company,” NYSE: XPEV and HKEX: 9868), a leading Chinese smart electric vehicle (“Smart EV”) company, today announces that the international model of their flagship electric SUV, XPENG G9, has received a five-star 2023 safety rating from Euro NCAP. Euro NCAP's five-star safety rating system aims to help consumers, their families and businesses compare vehicles more easily and identify the safest choice for their needs. The tests, which replicate real-life road danger scenarios, represent the European gold standard for comprehensive automotive safety testing. The rating recognises the XPENG G9's advanced body structure and comprehensive passive s
AS Tallink Grupp: Managers’ Transactions6.12.2023 11:00:00 CET | Press release
Person subject to the notification requirement Name: AS Infortar Position: Closely associated person (X) Legal person Person Discharging Managerial Responsibilities in Issuer Name: Hanschmidt, Ain Position: Member of the Supervisory Board Name: Pant, Eve Position: Member of the Supervisory Board Issuer: AS Tallink Grupp LEI: 529900QRMWAKKR3L9W75 Notification type: Initial Notification _____________________________________ Transaction date: 04.12.2023 Venue: Nasdaq OMX Tallinn Instrument type: Share ISIN: EE3100004466 Nature of the transaction: Acquisition Transaction details: (1): Volume: 105,178; Unit price: 0.68 EUR Aggregated transactions: (2): Volume: 105,178; Volume weighted average price: 0.68 EUR Anneli Simm Investor Relations Manager AS Tallink Grupp Sadama 5 10111 Tallinn E-mail Anneli.simm@tallink.ee
CDR-Life Announces First Patient Dosed in Phase 1 Study with Boehringer Ingelheim Evaluating Potential Treatment for Geographic Atrophy6.12.2023 11:00:00 CET | Press release
ZÜRICH, Switzerland, Dec. 06, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. today announced that the first patient has been dosed in the Phase 1 trial of BI 771716 for the treatment of geographic atrophy (GA). Licensed to Boehringer Ingelheim, BI 771716 is a highly specific antibody fragment of reduced size, enabling an optimized penetration through all retinal layers to the most critical target site driving GA disease pathology. The Phase 1 study (NCT06006585) is evaluating the safety, tolerability and pharmacokinetics of intravitreal single rising doses and multiple doses of BI 771716 as a potential treatment for GA. GA is a chronic and progressive, irreversible retinal disease that occurs in people with late-stage dry age-related macular degeneration (AMD) impacting the ability to see. More than 5 million people worldwide suffer from GA, of which more than 40% are legally blind. GA worsens with age, affecting 1 in 29 people above the age of 75 and 1 in 4 people above 90. Consequently, risi